Heart failure (HF) affects 6.2 million Americans and is increasing annually in its frequency. Treatment of HF has been at the forefront of medical advancements due to the financial burden on our health care system. As such, changes to the guidelines regarding standard of care have been evolving over the last decade with the recent additions of sacubitril-valsartan and sodium glucose co-transporter-2 inhibitors to standard of care in the treatment of HF. Despite the aforementioned expansions in treatment options, HF continues to have a significant impact on the American health care system. Most recently, a novel drug vericiguat that targets an unprecedented pathway for the treatment of HF was Food and Drug Administration approved for the management of patients with HF with a reduced ejection fraction with a recent hospitalization or need for outpatient intravenous diuretics. In clinical trials, vericiguat was associated with a reduction in death from cardiovascular causes and first hospitalization in comparison to placebo. The aim of this review is to provide a comprehensive literature analysis of the various trials surrounding the approval of vericiguat and to both inform and synthesize the data surrounding the clinical use of vericiguat. The introduction of Vericiguat should be considered as a treatment option in patients to decrease the mortality/morbidity of HF with reduced ejection fraction and to increase the quality of life.
Introduction:
Acetaminophen is one of the most widely used over the counter medications, used for its analgesic and antipyretic properties. NSAIDs have been known to raise blood pressure, but there have been limited studies looking at the effect of acetaminophen on blood pressure. Observational studies have shown contradictory results regarding the effect of acetaminophen on blood pressure.
Purpose:
We aimed to perform a systematic review and meta-analysis of the randomized controlled trials (RCTs) to compare the effect of acetaminophen vs placebo on systolic and diastolic ambulatory blood pressure.
Methods:
A systematic comprehensive search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was done in PubMed, Embase and Cochrane library for the RCTs investigating the effect of acetaminophen on blood pressure in patients compared to placebo. Standardized mean difference (SMD) and 95% confidence interval was used to compare the changes in blood pressure and p-values of <0.05 was considered as statistically significant. Finally, subgroup analysis was performed when possible.
Results:
Systematic search through April 2022 resulted in 3 relevant trials. The analysis showed that the patients receiving acetaminophen had significantly higher systolic blood pressure compared to those having placebo (SMD = 0.35, 95% CI = 0.08-0.63, p-value = 0.01). Moreover, subgroup analysis of the effect on hypertensive patients showed the significant change in systolic blood pressure as well (SMD = 0.38, 95% CI = 0.05-0.71, p-value = 0.02). In terms of diastolic pressure, our analysis showed that there is not any significant change in blood pressure when comparing acetaminophen and placebo (SMD = 0.18, 95% CI = -0.09-0.45, p-value = 0.19). This effect remains insignificant even after subgroup analyzing for hypertensive patients with SMD of 0.09 (95% CI = -0.34-0.52, p-value = 0.68).
Conclusion:
Our study demonstrated a significant correlation between the use of acetaminophen and elevated systolic blood pressure. This adds to concern regarding the safety of regular acetaminophen use, particular in patients with pre-existing hypertension or cardiovascular risk factors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.